MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first
six months' 2016 results on August 1, 2016 at 7:00 am CEST.
At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of MorphoSys AG
will host a public conference call and webcast to present MorphoSys's Half-Year
Report 2016 and provide further details on the Company's latest developments.
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
We request that you please dial in up to 10 minutes before the call to ensure a
prompt start and a secure line.
The presentation slides and webcast link will be available at the Company's
website at www.morphosys.com/conference-calls
A slide-synchronized audio replay of the conference will also be available at
the corporate website following the live event.
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties, Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Q2 2016 Conference Call Allert:
http://hugin.info/130295/R/2030354/755194.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2030354]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
Datum: 25.07.2016 - 14:00 Uhr
Sprache: Deutsch
News-ID 485094
Anzahl Zeichen: 3952
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Host Q2 2016 Conference Call on August 1, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
